Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

New combinations in the treatment of COPD: rationale for aclidinium–formoterol

Authors Incorvaia C, Montagni M, Makri E, Ridolo E

Received 15 December 2015

Accepted for publication 18 January 2016

Published 15 February 2016 Volume 2016:12 Pages 209—215

DOI https://doi.org/10.2147/TCRM.S82034

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Cristoforo Incorvaia,1 Marcello Montagni,2 Elena Makri,1 Erminia Ridolo2

1Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, 2Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

Abstract: The current guidelines on chronic obstructive pulmonary disease (COPD) recommend the prominent use of bronchodilators, including long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended only in patients with severe disease or frequent exacerbations. LABA–LAMA combinations are indicated when single bronchodilators are insufficient to control COPD. A number of LABA–LAMA combinations are available, based on twice-daily or once-daily administration according to the 12- or 24-hour duration of action, respectively. The aclidinium–formoterol combination is based on the new LAMA aclidinium bromide, which has a high selectivity for M3 muscarinic receptors and a fast onset of action, and the well-known LABA formoterol. Both drugs require twice-daily administration. The fixed-dose combination of aclidinium 400 µg/formoterol 12 µg has shown in randomized controlled trials fast and sustained bronchodilation that was greater than either monotherapy and provided clinically significant improvements in dyspnea and health status compared with placebo, also reducing the use of rescue medications. The overall incidence of adverse events was low and comparable to placebo. These data define the aclidinium–formoterol fixed-dose combination as a new treatment option for patients with COPD. The need for twice-daily administration could be an apparent disadvantage compared to the available once-daily LABA–LAMA combinations, but the immediately perceived benefit in reducing dyspnea due to the fast onset of action, as well as reported correct patient use and satisfaction with the Genuair inhaler might prove useful in favoring adherence.

Keywords: bronchodilators, COPD, LABA, LAMA, combination, efficacy, safety, inhalation device

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Striving for optimal bronchodilation: focus on olodaterol

Incorvaia C, Montagni M, Makri E, Riario-Sforza GG, Ridolo E

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:439-444

Published Date: 1 March 2016

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E

Drug Design, Development and Therapy 2014, 8:197-207

Published Date: 7 February 2014

Shrinking the room for invasive ventilation in hypercapnic respiratory failure

Scarpazza P, Incorvaia C, Melacini C, Cattaneo R, Bonacina C, Riario-Sforza GG, Casali W

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:135-137

Published Date: 15 March 2013

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy

Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'Albani I, Puccinelli P

Drug Design, Development and Therapy 2012, 6:117-123

Published Date: 18 May 2012

Seroprevalence of IgG anti-Toxocara species antibodies in a population of patients with suspected allergy

Qualizza R, Incorvaia C, Grande R, Makri E, Allegra L

International Journal of General Medicine 2011, 4:783-787

Published Date: 22 November 2011

Long-term survival in elderly patients with a do-not-intubate order treated with noninvasive mechanical ventilation

Scarpazza P, Incorvaia C, Amboni P, di Franco G, Raschi S, Usai P, Bernareggi M, Bonacina C, Melacini C, Cattaneo R, Bencini S, Pravettoni C, Riario-Sforza GG, Passalacqua G, Casali W

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:253-257

Published Date: 26 April 2011

The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children

Cristoforo Incorvaia, Simonetta Masieri, Silvia Scurati, et al

Journal of Asthma and Allergy 2011, 4:13-17

Published Date: 20 February 2011

Development of a sublingual allergy vaccine for grass pollinosis

Franco Frati, Silvia Scurati, Paola Puccinelli, et al

Drug Design, Development and Therapy 2010, 4:99-105

Published Date: 17 June 2010

Adherence issues related to sublingual immunotherapy as perceived by allergists

Silvia Scurati, Franco Frati, Gianni Passalacqua, et al

Patient Preference and Adherence 2010, 4:141-145

Published Date: 15 June 2010

Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: A number needed to treat study

Gian Galeazzo Riario-Sforza, Cristoforo Incorvaia, Fulvia Paterniti, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:315-319

Published Date: 21 August 2009

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010